Investigating Up-to-Seven Criteria and APRI (AST Platelet Ratio) as Prognostic Factors in Intermediate-Stage Hepatocellular Carcinoma Patients Who Received Transarterial Chemoembolization.
| Autor: | Inmutto N; Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Nimitrungtawee N; Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Srisuwan T; Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Kattipathanapong T; Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Jantarangkoon A; Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Puttisri O; Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Asian Pacific journal of cancer prevention : APJCP [Asian Pac J Cancer Prev] 2022 Nov 01; Vol. 23 (11), pp. 3939-3946. Date of Electronic Publication: 2022 Nov 01. |
| DOI: | 10.31557/APJCP.2022.23.11.3939 |
| Abstrakt: | Background: Transarterial chemoembolization (TACE) is one of the locoregional treatments for intermediate-stage hepatocellular carcinoma (HCC). Multidetector computed tomography (MDCT) is a widely used diagnostic tool for HCC. It can also evaluate tumor size, tumor number, and tumor invasion. This study aimed to determine the median survival time in intermediate-stage HCC patients who underwent TACE and to find out prognostic factors influencing patients' survival time after TACE. Methods: A computerized search of medical record database in Maharaj Nakorn ChiangMai Hospital from January 2016 to December 2019 revealed 187 intermediate-stage HCC patients who received TACE as the first-line treatment. Results: The median survival time of patients in this study was 9.9 months (95% CI: 8.3-11.6). The patients with aspartate aminotransferase-to-platelet ratio (APRI) less than 0.5 had a significantly better median survival time as compared with patients with APRI ratio more than 0.5; (13.2 months versus 9.9 months, p-value < 0.05). Univariate and multivariate Cox regression analysis demonstrated that tumor number > 7 and tumor size > 5 centimeters (cm) could be considered as independent parameters predicting poor overall survival time in the sufferers (HR 2.64 95%CI 1.68-4.15 and HR 2.38 95%CI 1.32-4.31, respectively). Conclusion: Based on our findings, patients with intermediate-stage HCC who received TACE had a lower median survival time compared to previous studies. However, we identified APRI less than 0.5, tumor size less than 5 cm, and tumor number less than 7 as prognostic factors improving survival time in intermediate-stage HCC patients. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|